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Background: The current standard of care for Glioblastoma Multiforme (GBM) consists of fractionated focal irradiation
with concomitant temozolomide (TMZ) chemotherapy. A promising strategy to increase the efficacy of TMZ is through
interference with the DNA damage repair machinery, by poly(ADP-ribose) polymerase protein inhibition(PARPi). The
objective of the present study was to investigate the therapeutic benefit of combination therapy in patient-derived
glioma stem-like cells (GSC).
Methods: Combination therapy feasibility was tested on established GBM cell lines U373 and T98. We developed an
in vitro drug-screening assay based on GSC cultures derived from a panel of primary patient tissue samples (n = 20) to
evaluate the effect of PARPi (ABT-888) monotherapy and combination therapy with TMZ. Therapeutic effect was
assessed by viability, double stranded breaks, apoptosis and autophagy assays and longitudinal microscopic cell
monitoring was performed. O-6-methylguanine-DNA methyltransferase (MGMT) status was determined by methylation
assay and protein expression by western blots.
Results: PARPi monotherapy was found to decrease viability by more than 25% in 4 of the 20 GSCs (20%) at 10 μM.
TMZ monotherapy at 50 μM and 100 μM was effective in 12 and 14 of the 20 GSCs, respectively. TMZ resistance to
100 μM was found in 7 of 8 MGMT protein positive cultures. Potentiation of TMZ therapy through PARPi was found in
90% (n = 20) of GSCs, of which 6 were initially resistant and 7 were sensitive to TMZ monotherapy. Increased induction
of double stranded breaks and apoptosis were noted in responsive GSCs. There was a trend noted, albeit statistically
insignificant, of increased autophagy both in western blots and accumulation of autophagosomes.
Conclusion: PARPi mediated potentiation of TMZ is independent of TMZ sensitivity and can override MGMT(-) mediated
resistance when administered simultaneously. Response to combination therapy was associated with increased double
strand breaks induction, and coincided by increased apoptosis and autophagy. PARPi addition potentiates TMZ
treatment in primary GSCs. PARPi could potentially enhance the therapeutic efficacy of the standard of care in GBM.
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Glioblastoma Multiforme (GBM) is the most common
primary brain tumor for which there is no curative
therapeutic option [1]. First-line treatment of GBM con-
sists of tumor resection, followed by fractionated focal
irradiation (IR) in combination with concomitant and* Correspondence: s.leenstra@erasmusmc.nl
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unless otherwise stated.adjuvant administration of the alkylating agent temozo-
lomide (TMZ). Despite recent advances in understanding
the molecular biology of GBM, the clinical perspective for
newly diagnosed patients remains poor. The addition of
TMZ to surgery followed by radiation has increased me-
dian survival from 12 to 15 months compared with IR
monotherapy [2]. Hence, the need for therapeutic agents
that can augment current treatment outcome is urgent.
It has been demonstrated that therapeutic efficacy
of this chemo-radiation regimen, apart from clinicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor [3,4] such as methylation of the O6-methylguanine-
DNA methyltransferase (MGMT) promoter gene and the
subsequent lack of expression of the MGMT protein
within GBM cells [5]. Several mechanisms have been iden-
tified that lead to the repair of alkylation-induced damage,
such as base-excision repair (BER), mismatch repair
(MMR) and homologous recombination (HR) repair [6,7].
The addition of DNA-repair system interfering agents may
therefore potentiate the efficacy of TMZ treatment. Poly
ADP Ribose Polymerase (PARP) proteins share the ability
to transfer an ADP-ribose moïety from nicotinamide
adenine dinucleotide (NAD+) to an acceptor protein and
facilitate the accumulation of multiple sequential (poly)
ADP-ribose units to the preceding one(s), a process termed
PARylation. These proteins have been demonstrated to be
essential in BER, after DNA damage induced by cytotoxic
agents. PARP protein inhibitors (PARPi) were demon-
strated to enhance therapeutic efficacy of several conven-
tional cytotoxic agents, such as alkylating chemotherapy.
One such agent, ABT-888 (Veliparib®), has been demon-
strated to primarily bind to PARP-1and PARP-2, and infer-
iorly to PARP-3 and PARP-4 [8]. In humans, PARP-1
activity is responsible for 85-90% of PAR production with
the remainder primarily attributable to PARP-2. Therefore,
we will reference PARPi function from here on as dimin-
ished activity of PARP-1 and PARP-2.
Low passage glioma stem cell (GSC) cultures have
been demonstrated to superiorly recapitulate genomic
and gene-expression profiles, when compared with GBM
cell lines and serum supplemented primary cultures
[9,10]. The investigation of therapeutic effect of com-
bined agents in patient derived material provides the
ability to identify predictors of responsiveness in vitro.
In the present study we investigated the sensitivity of a
large panel of patient derived GSCs to monotherapy
with both TMZ and PARPi. Additionally, we evaluated
the ability of PARPi to potentiate TMZ cytotoxicity at
varying clinically relevant doses. The ability of PARPi to
overcome TMZ resistance is addressed in the context of
MGMT expression in GSCs.
Methods
Cell cultures
All GSC primary cultures were derived from tumors of
operated patients from the Erasmus Medical Center
Rotterdam, The Netherlands. Prior to surgery, patients
sign informed consent as approved by the Institutional
Review Board of the Erasmus Medical Center Rotterdam.
Tumor grading was performed by the local pathologist
according to guidelines of the WHO grading of primary
brain tumors. Freshly resected tumor samples were disso-
ciated to establish primary cultures as described earlier
[11]. Serum free medium constitutes DMEM-F12 with1% penicillin/streptomycin, B27 (Invitrogen, Bleiswijk,
The Netherlands), human EGF (5 ug/ml), human basic
FGF (5 ug/ml) (both Tebu-Bio, Heerhugowaard, The
Netherlands) and heparin (5 mg/ml) (Sigma-Aldrich,
Zwijndrecht, The Netherlands). Tumor spheres were
dissociated and passaged regularly for experiments or
to derive material for characterization studies. T98 and
U373MG conventional cell cultures were acquired from
the American Type Culture Collection (ATCC, Manassas,
VA) and propagated on DMEM supplemented with 10%
fetal bovine serum and 1% penicillin + streptomycin.
Viability and proliferation assays
Patient-derived tumor spheres were dissociated with
Accutase™ (Invitrogen, Bleijswijk, The Netherlands), and
cell lines T98 and U373 with trypsin. Cells were seeded
at 1000 cells per well in 96 wells plates. For GSCs, wells
were coated with extracellular matrix coating (BD
Bioscience, Breda, The Netherlands). After 24 hours,
cells were treated with TMZ (Sun Pharmaceutical Indus-
tries, Mumbai, India), or ABT-888 (Selleckchem, Huissen,
The Netherlands), at indicated doses that have been
demonstrated clinically relevant [12,13]. Combination
therapy reagents were prepared by adding a mixed
reagent in culture medium at equal volumes to mono-
therapy. Vehicle controls constituted of equal DMSO
concentrations as needed for the dilution of TMZ ther-
apy. After 5 days, viability was measured by performing
the Cell Titer GLO™ assay according to the manufac-
turer’s instructions (Promega, Leiden, The Netherlands).
All experiments were carried out in triplicate. T98 and
U373 were used as positive and negative internal controls
during GSC-based drug-screening experiments. Read-out
was performed in a plate reader by measuring lumines-
cence (Tecan Infinite 200, Tecan Benelux, Giessen, NL).
Proliferation assays consisted of longitudinal imaging of
cell confluency in the Incucyte HD Live Cell imaging in-
cubator. Cells were seeded in 96 wellsplates and placed
into the Incucyte incubator. Phase contrast images were
acquired at 1-3hr intervals and confluence per well was
calculated using a software platform supplied by the
manufacturer (Essen Bioscience, Hertfordshire, UK).
Combination indexes of PARPi and TMZ combination
therapy were obtained through Cell Titer GLO read-out,
and calculated according to the Chou-Talalay procedure
[14]. In short, serial dilution experiments with TMZ and
ABT-888 monotherapy were carried out in order to de-
termine the IC50 of each drug separately. Based on the
Y-intercept and the slope of the curve derived from
linearization of the viability data, the IC50 was calcu-
lated. Subsequently, ABT-888 and TMZ combination
experiments were dosed by combining 3 stepwise deriva-
tives (with 3 fold increases or decreases) of the IC50
value of both drugs in T98 and U373 respectively. Based
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dosages needed to elicit a decrease of viability (fraction
affected, Fa) at a specific dose of each (combination of )
agent(s) can be calculated. Subsequently the dose reduc-
tion index (DRI) of combination therapy is the ratio be-
tween the monotherapy dose and the combination
therapy dose for a given Fa. The combination index
is thus provided as the combined 1/DRI of both agents
(1/DRItmz + 1/DRIabt-888), which should remain below 1
in order to demonstrate synergy.
Double stranded breaks assays
To determine the induction of DSBs in GSCs, cells were
seeded at a concentration of 2.5x104 cells per well in
matrigel coated 96 wells plates. Experiments were
carried out as instructed by the manufacturer of the
OxiSlect DNA Double Strand Break Staining Kit (Cell
Bio Labs Inc, San Diego, CA, USA). In short, cells were
incubated overnight and treated next day with 100 uM
TMZ, 10 uM ABT-888 or combination therapy with
both agents. Positive controls consisted of etoposide
(0.1 mM) treated cells, whereas for negative controls
we used non-treated controls. Readout was performed
16 hours post-treatment. Cells were fixed in 4%PFA/PBS,
washed and stained according to manufacturer’s protocol
with primary antiγH2Ax antibody solution (1:100) and
counterstained with secondary FITC conjugated anti-
body solution (1:100). After washing, cells were incu-
bated in the Incucyte and yH2Ax positive cells were
counted per well with software as provided by the
Incucyte manufacturer.
Apoptosis and autophagy assays
To determine the induction of apoptosis or autophagy
by mono- or combination-therapy GSCs were plated out
in similar conditions with regard to culture conditions,
drug dosing and preparations, and cell seeding, as de-
scribed for the viability assays. The Cell Player Caspase
3/7 reagent (Essen Bioscience, Hertfordshire, UK) was
added in a 1:1000 dilution to the culture medium at
the time of treatment administration (according to man-
ufacturers instructions). Read-out was performed after
48 hrs post-treatment by counting the ratio between
apoptotic cells and total cells per well, using algorithms
provided within the software of the Incucyte FLR.
For autophagy experiments, cells were seeded, treated
and cultured as described above for previous in vitro ex-
periments. To determine the induction of autophagy, we
used the Cyto-ID Autophagy detection kit (Enzo Life
Sciences, Raamsdonksveer, The Netherlands). This kit
provides a monodansylcadaverine based dye that specif-
ically stains autophagosomes [15]. To this end, cells were
washed 16hrs post-treatment with assay buffer provided
by the manufacturer. Next, cells were stained with theCyto-ID green detection reagent for 30 minutes and
subsequently washed twice more with assay buffer and
cells were imaged in the Incucyte FLR for the detection
of autophagosomes. Incucyte software was used to
process imaging data. First a threshold was set for cir-
cumference and fluorescence intensity to identify autop-
hagosomes. Next the autophagosomes per well were
calculated using algorithms provided by the Incucyte
manufacturer.
MGMT methylation assay and western blotting
All samples used were derived from GS cultures pas-
saged no more than 7 times. DNA and protein extrac-
tion was derived from fresh frozen pellets. Quantitative
PCR on MGMT promoter methylation was assessed as
previously decribed [16]. The following methylation spe-
cific primers were used F: TTTCGACGTTCGTAG
GTTTTCGC and R: GCACTCTTCCGAAAACGAAA
CG. The un-methylated specific primers were F:
TTTGTGTTTTGATGTTTGTAGGTTTTTGT and R:
AACTCCACACTCTTCCAAAAACAAAACAQ. Western
blots for MGMT protein expression were performed as
follows. Samples were cultured, treated as indicated,
and sequentially pelleted, washed twice in ice-cold PBS,
and lysed in RIPA buffer with proteinase inhibitor (1%).
Protein concentration was measured by performing the
Bradford assay. The samples were diluted in Laemli buffer
and run on 10% SDS-PAGE gel for electrophoresis. After
running the gel, proteins were transferred to PVDF mem-
branes in a BIO-RAD transfer system. Membranes were
blocked with 5% milk in TBS-Tween (0.2%) and stained
with primary antibodies at 4°C over night. After washing,
secondary antibodies were applied for 1 hour with subse-
quent washing steps. Protein detection was achieved by
using ECL chemiluminescent detection reagent (Pierce,
Thermo Scientific Etten-Leur,NL). Antibodies used are
anti-MGMT (Abcam, Cambridge MA, USA), LC3B (Cell
Signaling, Danvers, MA, USA) and anti-β-actin (Clone C4,
Millipore Amsterdam, The Netherlands).
Statistical analysis
Data are presented as averages ± standard deviations as
compared to non-treated controls. Statistical analysis
was performed using the paired two-tailed Student’s
t-test. Statistical significance was defined as p <0.05.
Enhancement factors were determined as the ratio between
the most effective single agent (between ABT-888 and
TMZ) and the effect of combination therapy.
Results
PARP inhibition potentiates TMZ in sensitive and resistant
conventional celllines
The addition of PARPi to TMZ treatment was tested in
two conventionally used GBM cell lines, T98 and U373
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protein status have been previously reported [17]. Quan-
tification of cytotoxicity was assessed by cell viability as
well as monolayer confluency (Figure 1A and B). In ac-
cordance with previous reports [18], U373 was sensitive
to TMZ monotherapy, whereas T98 was resistant
(p>0.05 for both dosages compared to non-treated con-
trol). Conversely, T98 was sensitive to PARPi monother-
apy whereas U373 was not. Comparative analysis of
confluency and ATP-based viability generally correlated
well. However, T98 susceptibility for ABT-888 mono-
therapy appeared more pronounced when assessed for
viability than the confluency results suggest. Microscopic
examination (Figure 1C) revealed fewer viable cells andFigure 1 PARPi potentiates TMZ therapy in conventional GBM cell lin
cell lines treated at the indicated doses with TMZ and PARPi. Viability is ind
columns indicate significance between two conditions with a p-value <0.05. I
controls, the significance of combination therapy when compared to non-trea
B) Viability as a measure of confluence per well as measured by microscopy. R
U373 and T98. From left to right the PARPi dosage increases from 0 to 10 uM.
Note the differential effect of PARPi monotherapy between T98 and U373. D) C
U373. PARPi with TMZ combination therapy is synergistic in T98 but not in U37
TMZ and PARPi at the indicated Fa. CI > 1 demonstrates antagonistic effect of cdrifting debris suggestive of cytotoxic effect of ABT-888
at 10 uM in T98 cells, which was not apparent in U373.
PARPi potentiated TMZ therapy in case of TMZ
50 μM in T98. Adding PARPi resulted in a dose
dependent decrease of viability by 42% ±11% (2.5 μM
PARPi) and 82% ±16% (10 μM PARPi). Similar results
were found for the combination of TMZ at 100 μM with
PARPi at 10 μM in T98 (p<0.001). In U373, combination
treatment of TMZ 50 μM with 2.5 uM PARPi was more
effective than mono-treatment, however, the net de-
crease was small (10% ±2.6%, p<0.05), while not signifi-
cant for TMZ 100 μM/10 uM PARPi.
To evaluate synergy between the two agents in a system-
atic manner, the Chou-Talalay combination index (CI) wases on serum-supplemented medium. A) Viability of T98 and U373
icated as a measure of ATP conversion into luminescence. Lines above
f monotherapy with TMZ is significant when compared to non-treated
ted controls is related and therefore not defined as such in the figure.
ead out is performed at 5 days post treatment. C) Microscopic images of
Lower panel depicts combination therapy with TMZ at indicated dosages.
ombination Index (CI) plotted against Fraction affected (Fa) for T98 and
3. CI < 1 demonstrates synergistic interaction of combination therapy with
ombination therapy at the indicated Fa.
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T98 was comparatively resistant to TMZ with an IC50 at
5 days of 415.5 μM (R2 = 0.97), while the IC50 of U373
was 66.8 uM (R2 = 0.94) at 5 days. T98 was relatively sensi-
tive to PARPi with an IC50 of 16.46 μM (R2 = 0.98) com-
pared to an IC50 of 58.6 uM (R2 = 0.97) for U373. Next,
the combination index (the ratio between dose reduction
of combined treatment and monotherapy with either
agents individually) was plotted. For T98 the combination
of PARPi and TMZ was found synergistic with a CI below
1 for all Fa (fraction affected) (Figure 1D). In contrast, the
CI U373 consistently demonstrated a CI>1, suggestive of
antagonized cytotoxicity of ABT-888 when combined with
TMZ in this cell line.
PARPi and TMZ monotherapy screening experiments
in GSCs
Molecular characteristics as found in primary GBM tis-
sue, are inferiorly recapitulated in conventional cell lines
such as T98 and U373, when compared to early passages
of serum-free patient-derived cultures [10,19]. Therefore,
we tested 20 GSC cultures from high-grade malignant
glioma for the PARPi ABT-888 and TMZ sensitivity
(overview of clinically relevant information in Table 1).Table 1 Overview of GSC panel drug screening results
GS ID Histology Age OS MGMT Blot/Methyl PARPi TMZ
GS249 GBM 53 215 - / ND 0.30 0.66
GS187 GBM 73 394 - / UM 0.12 0.55
GS41 AOD 64 1316 ND 0.11 0.61
GS125 GBM 75 234 + / UM 0.21 0.71
GS203 GBM 64 554 - / M 0.39 0.61
GS184 GBM 50 833 - / M 0.16 0.74
GS186 GBM 49 792 - / M 0.21 0.74
GS224 GBM 58 101 - / M 0.17 0.73
GS177 GBM 63 843 - / M 0.20 0.76
GS182 GBM 70 835 - / M 0.38 0.51
GS200 GBM 57 321 - / ND 0.48 0.35
GS143 GBM 54 395 - / ND 0.60 0.32
GS126 GBM 41 962 + / M 0.27 0.06
GS79 GBM 71 384 + / UM 0.11 0.23
GS124 GBM 71 1033 + / ND 0.22 −0.11
GS148 AOD 82 97 + / UM 0.20 −0.07
GS173 GBM 68 138 + / ND −0.05 0.14
GS204 GBM 50 18 + / UM 0.07 0.02
GS161 GBM 62 264 + / M 0.17 −0.02
GS160 GBM 46 46 + / UM 0.07 0.16
The separation between TMZ sensitive and resistant groups is based on monothera
Student’s T-test of the most effective single agent compared to combination therapy
of composing this article. Abbreviations as followed; AOD = Anaplastic Oligodend
MGMT = O6-methylguanine-DNA methyltransferase, Blot = Western blotting result
which can be Methylated or UnMethylated). ND = Not determined.GSC cultures were labeled sensitive if more than 25% re-
duction in viability was measured as compared to non-
treated controls. For PARPi monotherapy at 10μM, this
was found in 4/20 cultures (20%), (Figure 2A).
Sensitivity to TMZ was tested at two standard concen-
trations of 50 μM (low dose) and 100 μM (high dose).
These concentrations are derived from experiments with
T98 and U373 as the optimal concentrations to detect
additional effect by combination therapy in both TMZ
sensitive and resistant cultures, within physiological
ranges as found in plasma and CSF of patients treated
with TMZ [20]. Low dose TMZ induced more than
25% viability loss in 5/20 cultures (25%) (Figure 2B).
High dose TMZ treatment had therapeutic effect in
12/20 cultures (55%). Based on these results we cate-
gorized the 20 GSC cultures into PARPi and TMZ
resistant and sensitive cultures based on the initial
monotherapy screen (Table 1). Six of the 20 cultures
were tested at least three times for reproducibility of
the results, which demonstrated consistent TMZ and
PARPi therapeutic efficacy profiles over multiple pas-
sages (data not shown).
Since therapeutic response of malignant glioma to
TMZ is known to be highly correlated with MGMTEnhancement factor
TMZ 50
p-value Enhancement factor
TMZ 100
p-value
3.06 0.01 2.92 0.03
2.22 0.00 2.31 0
1.74 0.08 0.92 0.19
1.59 0.17 1.78 0.06
1.68 0.01 1.71 0.01
1.40 0.10 1.66 0.01
1.30 0.03 1.49 0
1.15 0.20 1.20 0.03
1.14 0.01 1.15 0.2
1.14 0.02 1.31 0.05
1.16 0.02 1.18 0.08
1.17 0.40 1.32 0.09
1.68 0.02 1.69 0.01
2.11 0.00 2.48 0
1.19 0.40 1.19 0.06
1.15 0.80 1.15 0.06
1.24 0.07 1.73 0.01
1.17 0.03 1.17 0.04
0.80 0.04 0.80 0.2
0.83 0.03 0.75 0
py results for TMZ 100 μM results. Significance is depicted as a p-value derived
. For OS, boxes without shading depict patients that were alive at the moment
roglioma, GBM = Glioblastoma Multiforme, OS = Overall Survival in days,
s which can be positive (+) or negatieve (−), Methyl = Methylation assay
Figure 2 PARPi and TMZ monotherapy efficacy in GS cultures. A) Panel of GS cultures tested for sensitivity to PARPi at 10 uM. Readout of
viability was performed at day 5 and is depicted as a percentage when compared to non-treated controls. * Illustrates a p-value <0.05. B) GS
culture panel tested against indicated concentrations in uM of TMZ monotherapy. Viability at day 5 is indicated as percentages when compared
to paired non-treated controls. * indicates p < 0.05 as compared to non treated controls. C) Overview of western blotting results derived from GS
cultures. MGMT protein expression is indicated with actin protein expression used as a loading control. TMZ sensitivity is indicated with an S (sensitive),
R (resistant) and ND (TMZ sensitivity not determined in monotherapy screen). For several GSCs protein isolates were loaded in separate runs as
technical controls.
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MGMT protein expression [5,21], we performed West-
ern blotting of MGMT protein in 19 out 20 cell cultures
tested in our initial drug screening (Figure 2C). MGMT
was expressed in 9 GSC cultures (MGMT(+)), of which
8 were found to be resistant to 100 μM of TMZ. Con-
versely, all 11 MGMT negative (MGMT(-)) cultures
were found sensitive to TMZ therapy. Together, TMZ
sensitivity was highly correlated to MGMT expression
(p=0.007). In addition we determined the promotor
methylation status, which generally correlated well with
protein expression (n = 11/14, 78%). Interestingly, the
sensitivity to ABT-888 was also correlated to MGMT ex-
pression, since MGMT expressing GSCs were signifi-
cantly more resistant to ABT-888 10 uM monotherapy
compared to MGMT negative GSCs (p=0.01).
PARPi addition potentiates TMZ treatment in primary GSCs
To determine the ability of the PARPi ABT-888 to po-
tentiate TMZ efficacy, we evaluated the therapeutic ef-
fect of combination therapy in the aforementioned GSC
cultures (n=20). Enhancement factors were calculated as
the ratio between the most effective drug in monother-
apy and the effect of combination therapy. Efficacy en-
hancement by combination therapy was determined asan enhancement factor >1. As shown in Table 1, en-
hancement of 50 μM TMZ by10 uM PARPi was found
in 18 of 20 cultures (90%) of which 10 cultures had a
p-value of <0.05. Average and median decrease of
viability as compared to TMZ monotherapy was 22.8%
and 21.9%, respectively. For high dose TMZ monother-
apy, 17 out of 20 (65%) cases were potentiated of which
11 had a p-value <0.05. In this group the average and me-
dian reduction in viability was 23% and 28.8% (Table 1).
Except for GS41, enrichment factors between high and
low dose TMZ were similar or increased with the higher
dosing of TMZ, suggesting a dose response effect of
combination therapy. In conclusion, 18 out of 20 GSC
cultures were coined responders to combination ther-
apy (R), and two MGMT(+) cultures were coined
non-responders (NR).
We found that PARPi potentiated four of the MGMT(+)
GSC cultures (p<0.05); at both low and high dose TMZ.
Similarly, in 4 out of 8 MGMT negative cultures we dis-
covered additive effect of combination therapy (p<0.05).
Student’s t-test revealed no significant difference between
MGMT(+) or MGMT(-) GSCs with regard to ABT-888
potentiation of TMZ-therapy (p=0.71 low dose, and p=0.50
high dose respectively). Similarly, TMZ sensitivity as deter-
mined by monotherapy screening was not correlated to
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dose TMZ, respectively). In the single culture (GS173) for
which the lack of MGMT expression was not correlated to
TMZ sensitivity, we found PARPi mediated potentiation of
TMZ as well. Thus, PARPi can potentiate TMZ efficacy re-
gardless of the sensitivity to TMZ or MGMT status.
PARP inhibition increases TMZ induced double stranded
breaks, autophagy and apoptosis in GSCs
The progression of alkylation based single stranded
breaks (SSBs) to double stranded breaks (DSBs) has been
proposed to be fatal in cancer cells. While MGMT can
facilitate repair of SSBs, the rationale behind the
addition of ABT-888 to TMZ is to comprise the DNA-
repair cascade needed to prevent the induction of DSBs
after alkylation induced SSB formation. To address this
proposed role of DSB induction as an outcome of thera-
peutic efficacy in our GSC panel, three MGMT(-) and
two MGMT(+) GSCs were tested for DSB induction
when treated with TMZ, ABT-888 or combination ther-
apy. The induction of DSBs by TMZ monotherapy was
significant (p < 0.01) in 2 out of 3 MGMT(-) GSCs
(Figure 3A). Monotherapy with ABT-888 did not yield a
significant increase in DSB induction. Interestingly, DSB
induction was not apparent in one non-responder
GS160 (MGMT(+)), suggestive of the premise that DSB
induction is needed for combination therapy to potenti-
ate TMZ-monotherapy.
Next we assessed the induction of apoptosis and au-
tophagy, two pathways implicated to be upregulated in
response to both TMZ and PARP inhibitor treatment
[22-24]. We found that, in GS79 (MGMT(+), R), apop-
tosis was significantly (p<0.05) increased by combination
therapy as compared to monotherapy (Figure 3B). The
resistance to apoptosis induction following drug admin-
istration in GS160 further substantiated the hypothesis
that DSB induction is mandatory for cell death after
combination therapy. Autophagy has been implicated
both in the induction of senescence after cytotoxic insult
to facilitate DNA repair, as well as the induction of cas-
pase dependent cell death (apoptosis). The induction of
autophagy by therapeutic agents can be monitored
through the accumulation of autophagic vacuoles by
fluorescent microscopy or the conversion of LC3B-I into
the lipidated LC3B-II [25]. We found that both TMZ
and ABT-888 induced autophagy in GS79 (Figure 3C)
through a fluorescence based autophagy induction
monitoring kit. In addition, combination therapy was
found that have an additive effect with regard to the
induction of autophagosomes on microscopic imaging
(Figure 3C-D). Furthermore, the conversion of LC3B-I to
LC3B-II, a golden standard for the assessment of autoph-
agic flux [26], demonstrated to be increased in combin-
ation therapy on western blot (Figure 3E).Discussion
We here report the potential of ABT-888 as an additive
to TMZ chemotherapy for the treatment of GBM. ABT-
888 is a selective inhibitor of both PARP-1 and PARP-2
protein function, which are together responsible for the
majority of PAR activity [8]. The results presented here,
demonstrate that PARPi decreases proliferation and via-
bility of the glioma cell line T98 and of a substantial sub-
set of patient-derived GSCs. Furthermore, combined
treatment with PARPi and TMZ leads to significant po-
tentiation of therapeutic efficacy in the majority of
GSCs, irrespective of MGMT protein expression. In
addition, we found that MGMT+ GSCs are also signifi-
cantly more resistant to ABT-888 monotherapy, as com-
pared to MGMT(-) GSCs. We have found evidence
that the potentiation of TMZ therapy by ABT-888 is
dependent on the induction of DSBs, which coincides
with increased apoptosis and autophagy in responsive
cells.
Several studies have demonstrated the feasibility of
PARPi as an adjuvant in the treatment of malignancies
[27]. PARP activity has been implicated in both single
stranded break (SSB) repair and double stranded break
(DSB) repair [28]. Indeed, PARPi increased the efficacy
of both TMZ and other alkylating agents in preclinical
models of GBM and other solid tumors [29,30]. Al-
though previous studies have demonstrated the feasibil-
ity of this strategy in preclinical models based on serum
supplemented conventional cell lines [29,31,32], we here
address this form of combination therapy in a panel of
patient-derived GSCs. This is important since conven-
tional cell lines have been demonstrated to poorly mimic
the genomic and transcriptomic landscape of GBM [19].
In addition, GSCs have been postulated to play an im-
portant role in therapy resistance to current standard of
care for patients [33-36]. The results for TMZ mono-
therapy in our GSC panel are in congruence with previ-
ous publications [37-40] and reproduce MGMT protein
expression and subsequent TMZ resistance as found in
parental tumors [41]. Therefore, this study also confirms
that GSC panels are a suitable platform for assessing the
potential of TMZ combination therapy with other prom-
ising agents.
Although it is expected for most GBM samples to be
resistant to monotherapy with PARPi, since most GBM
have intact DNA-repair-signaling pathways, testing for
ABT-888 monotherapy effect demonstrated that a
substantial (20%) part of our panel was sensitive to
clinically relevant dosages of ABT-888. This has not
been demonstrated in patient derived glioma samples
with ABT-888 before, although other PARPi have had
similar effects in conventional cell lines [32]. Therefore,
we conclude that PARPi could be beneficial to therapeutic
efficacy in GBM, apart from interacting synergistically
Figure 3 PARP inhibition increases TMZ induced double stranded breaks, autophagy and apoptosis in GSCs. A) DSB induction is
significantly enhanced by combination therapy. GSCs, MGMT(+) and MGMT(-) were scored for γH2Ax positive cells, as an indicator for DSB
induction,16 hrs post-treatment. GS160 results are all significant as compared to non-treated controls. For the other cultures, significance is
indicated as described in the following; * indicates p < 0,05 as compared to non-treated controls. # indicates p < 0.05 as compared to
monotherapy. R = combination therapy responder, NR = non-responder. B) Apoptosis induction is significantly enhanced by combination
therapy in responder GSCs but not in non-responders. Wells were scored for apoptosis positive cells by live imaging. Read out was performed at
48 hrs post-treatment. Apoptotic cells were significantly (p < 0.05) increased after combination therapy as compared to monontherapy in
GSC79. For GS160 cells were not affected by TMZ/ABT-888 combination therapy while the positive control (etoposide 0.1 mM) was successfully
inducing apoptosis. C) TMZ and ABT-888 induce autophagy in GS79, which is augmented by combination therapy. Autophagosomes were
counted per well and compared to non-treated controls. Readout was performed 16 hrs post-treatment. Compared to controls, all treatment
conditions were significantly increased p < 0.05. However, combination therapy vs. monotherapy with ABT-888 or TMZ was found not significantly
increased (p = 0.3 and p = 0.4). D) Representative images acquired by the Incucyte FLR of GS79 stained for autophagosomes at indicated treatment
conditions. Note the accumulation of speckled dots in treated cells, specifically localized in enlarged cytopathic cells. E) Combination therapy
enhances autophagic flux as compared to monotherapy in GS79. Western blot 24 hrs post-treatment indicates the accumulation of LC3-II
(lipidated isoform) that is indicative for increased autophagic flux. Actin blots serve as loading controls.
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ase and tensin homologue (PTEN) deficient cells to be
particularly vulnerable to PARPi monotherapy through
compromised homologous recombination repair [7]. For
T98, susceptibility to PARPi could be related to a mutation
in the PTEN gene, as reported for this cell line [42]. In
GBM tissue profiling studies, PTEN signaling has been
demonstrated to be dysfunctional in 40-65% of GBM cases
[43,44]. However, other genes have also been implicated in
the efficacy of PARPi in vitro as well, such as BRCA-1/2 orCDK5 [45,46]. Future research on PARPi therapy may
therefore benefit from focused research on the identifica-
tion of predictive molecular signatures for the susceptibil-
ity to PARPi mono- or combination therapy in malignant
glioma.
Our study shows that PARPi enhances TMZ chemo-
therapy in 18 out of 20 cultures at varying doses (90%).
The potentiating effect of PARPi to TMZ is found in
both TMZ resistant and sensitive cultures. Combination
therapy was effective in 6 out of 8 MGMT expressing
Balvers et al. Journal of Translational Medicine  (2015) 13:74 Page 9 of 10GSC cultures, suggesting that the additive effect is inde-
pendent of MGMT status. At the time of finalizing this
manuscript, Tentori and colleagues, published a similar
study that demonstrated synergistic effect of combined
PARPi (inhibitor GPI-15427) and TMZ therapy in a
panel of 10 GSCs, data which are largely analogous with
our findings [47]. These results indicate that PARPi
has the potential to improve therapeutic efficacy of
TMZ in both responders and non-responders to TMZ
monotherapy.
Since the current chemo-irradiation treatment regi-
men has considerable side-effects, the possible potenti-
ation of TMZ by PARPi may also be considered in the
context of TMZ dose reduction, leading to reduced side-
effects, and prolonged therapeutic dosing in patients
undergoing chemo-irradiation. As combination therapy
efficacy may be unrelated to MGMT status, this may
provide for an interesting alternative to patients with a
recurrence after TMZ treatment. As such, other alkylat-
ing agents (e.g CCNU in the context of PCV, which is
frequently used for recurrent oligodendroglioma) may
be of considerable interest to study in combination with
PARPi [48].
The mechanisms through which PARPi enhances
TMZ induced cytotoxicity may be ambiguous. For one,
after the induction of SSBs by TMZ, PARPi prevents the
binding of PARP1-2 to damaged DNA foci to facilitate
BER. The PARPi mediated prevention of BER enhances
the formation of DSBs, which would eventually be lethal.
Our DSB and apoptosis induction assays provide com-
pelling evidence that this hypothesis holds truth in com-
bination therapy responder GSCs. Next to that, the
induction of autophagy after TMZ or ABT-888 might
provide an alternative mode of programmed cell death
that is induced after combination therapy. Whereas
monotherapy might induce autophagy as a mode of cel-
lular adaptation to the cytotoxic event, the cumulative
stress elicited by combination therapy might induce au-
tophagic cell death, which has been described as a con-
text dependent mode of programmed cell death induced
after a tipping point of autophagic flux is reached [49].
Conclusion
This study underscores the potential of PARPi as an en-
hancer of TMZ treatment of patients with GBM. Fur-
thermore, in select cases PARPi could elicit therapeutic
effect as a single agent. We have demonstrated the effi-
cacy of PARPi in GSCs, which are a more relevant
in vitro model for GBM than the conventional cell lines
used previously. PARPi-mediated potentiation of TMZ
therapy is independent of TMZ monotherapy sensitivity
or MGMT protein expression, which makes PARPi a
promising drug for addition to the current standard of
care chemo-irradiation regime.Competing interests
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